Dean R. Tolan

Dean R. Tolan

Auto-generated profile, based on publicly available information

Dean R. Tolan

Department of Biology, Boston University, Boston, USA

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Amyloid
Verified
Journal Article
Closed access
PDF file
CMChica Mori
Chica Mori
ESEdward T. Spooner
Edward T. Spooner
KWKrystyna E. Wisniewski
Krystyna E. Wisniewski
Thomas WisniewskiThomas Wisniewski
Thomas Wisniewski
HYHaruyasu Yamaguchi
Haruyasu Yamaguchi
CLCynthia A. Lemere
Cynthia A. Lemere
Alzheimer's disease (AD) brains display A beta (Aβ) plaques, inflammatory changes and neurofibrillary tangles (NFTs). Converging evidence suggests a neuronal origin of Aβ. We performed a temporal study of intraneuronal Aβ accumulation in Down syndrome (DS) brains. Sections from temporal cortex of 70 DS cases aged 3 to 73 years were examined immunohistochemically for immunoreactivity (IR) for the Aβ N-terminal, the Aβ40 C-terminus and the Aβ42 C-terminus. N-terminal antibodies did not detect intracellular Aβ Aβ40 antibodies did not detect significant intracellular Aβ, but older cases showed Aβ40 IR in mature plaques. in contrast, Aβ42 antibodies revealed clear-cut intraneuronal IR. All Aβ42 antibodies tested showed strong intraneuronal Aβ42 IR in very young DS patients, especially in the youngest cases studied (e.g., 3 or 4 yr. old), but this IR declined as extracellular Applaques gradually accumulated and matured. No inflammatory changes were associated with intraneuronal Aβ. We also studied the temporal development of gliosis and NFT formation, revealing that in DS temporal cortex, inflammation and NFT follow A β deposition. We conclude that Aβ42 accumulates intracellulary prior to extracellular Aβ deposition in Down syndrome, and that subsequent maturation of extracellular Aβ deposits elicits inflammatory responses and precedes NFTs.

10 March 2023 in Science
Verified
Journal Article
Closed access
KHKevin G. Hicks
Kevin G. Hicks
ACAhmad A. Cluntun
Ahmad A. Cluntun
HSHeidi L. Schubert
Heidi L. Schubert
SHSean R. Hackett
Sean R. Hackett
JBJordan A. Berg
Jordan A. Berg
JRJared Rutter
Jared Rutter
Metabolic networks are interconnected and influence diverse cellular processes. The protein-metabolite interactions that mediate these networks are frequently low affinity and challenging to systematically discover. We developed mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically (MIDAS) to identify such interactions. Analysis of 33 enzymes from human carbohydrate metabolism identified 830 protein-metabolite interactions, including known regulators, substrates, and products as well as previously unreported interactions. We functionally validated a subset of interactions, including the isoform-specific inhibition of lactate dehydrogenase by long-chain acyl–coenzyme A. Cell treatment with fatty acids caused a loss of pyruvate-lactate interconversion dependent on lactate dehydrogenase isoform expression. These protein-metabolite interactions may contribute to the dynamic, tissue-specific metabolic flexibility that enables growth and survival in an ever-changing nutrient environment.

23 April 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MLMiguel A. Lanaspa
Miguel A. Lanaspa
AAAna Andres-Hernando
Ana Andres-Hernando
DODavid Orlicky
David Orlicky
CCChristina Cicerchi
Christina Cicerchi
Cholsoon jangCholsoon jang
Cholsoon jang
DTDean R. Tolan
Dean R. Tolan
Increasing evidence suggests a role for excessive intake of fructose in the Western diet as a contributor to the current epidemics of metabolic syndrome and obesity. Hereditary fructose intolerance (HFI) is a difficult and potentially lethal orphan disease associated with impaired fructose metabolism. In HFI, the deficiency of aldolase B results in the accumulation of intracellular phosphorylated fructose, leading to phosphate sequestration and depletion, increased adenosine triphosphate (ATP) turnover, and a plethora of conditions that lead to clinical manifestations such as fatty liver, hyperuricemia, Fanconi syndrome, and severe hypoglycemia. Unfortunately, there is currently no treatment for HFI, and avoiding sugar and fructose has become challenging in our society. In this report, through use of genetically modified mice and pharmacological inhibitors, we demonstrate that the absence or inhibition of ketohexokinase (Khk), an enzyme upstream of aldolase B, is sufficient to prevent hypoglycemia and liver and intestinal injury associated with HFI. Herein we provide evidence for the first time to our knowledge of a potential therapeutic approach for HFI. Mechanistically, our studies suggest that it is the inhibition of the Khk C isoform, not the A isoform, that protects animals from HFI.

1 February 1990 in The Lancet
Verified
Journal Article
Closed access
NCN.C.P. Cross
N.C.P. Cross
TCT.M. Cox
T.M. Cox
RFR. de Franchis
R. de Franchis
GSG. Sebastio
G. Sebastio
CDC. Dazzo
C. Dazzo
RGR. Gitzelmann
R. Gitzelmann

1 June 1988 in Cell
Verified
Journal Article
Closed access
NCNicholas C.P. Cross
Nicholas C.P. Cross
DTDean R. Tolan
Dean R. Tolan
TCTimothy M. Cox
Timothy M. Cox

1 December 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CLCarolyn Ritterson Lew
Carolyn Ritterson Lew
DTDean R. Tolan
Dean R. Tolan
In cancer, glucose uptake and glycolysis are increased regardless of the oxygen concentration in the cell, a phenomenon known as the Warburg effect. Several (but not all) glycolytic enzymes have been investigated as potential therapeutic targets for cancer treatment using RNAi. Here, four previously untargeted glycolytic enzymes, aldolase A, glyceraldehyde 3-phosphate dehydrogenase, triose phosphate isomerase, and enolase 1, are targeted using RNAi in Ras-transformed NIH-3T3 cells. Of these enzymes, knockdown of aldolase causes the greatest effect, inhibiting cell proliferation by 90%. This defect is rescued by expression of exogenous aldolase. However, aldolase knockdown does not affect glycolytic flux or intracellular ATP concentration, indicating a non-metabolic cause for the cell proliferation defect. Furthermore, this defect could be rescued with an enzymatically dead aldolase variant that retains the known F-actin binding ability of aldolase. One possible model for how aldolase knockdown may inhibit transformed cell proliferation is through its disruption of actin-cytoskeleton dynamics in cell division. Consistent with this hypothesis, aldolase knockdown cells show increased multinucleation. These results are compared with other studies targeting glycolytic enzymes with RNAi in the context of cancer cell proliferation and suggest that aldolase may be a useful target in the treatment of cancer.